Sorry, but Beau's data is factual and easily confirmed.
What they're doing is typical of many OTC issuers. It isn't likely to draw the attention of the SEC, as, while they may have made some errors in their filings, or made statements or projections that haven't (yet) panned out, they're at least trying.
News 
Market Data 
Discover 
AI
